Bioatla announces $65 million underwritten offering of its common stock

San diego, nov. 04, 2022 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that it has agreed to sell 9,745,128 shares of its common stock at a price of $6.67 per share in an underwritten offering. the gross proceeds of the offering to bioatla before deducting estimated underwriting discount and commissions and estimated offering expenses are expected to be approximately $65 million. the offering is expected to close on or about november 8, 2022, subject to the satisfaction of customary closing conditions.
BCAB Ratings Summary
BCAB Quant Ranking